药明生物(02269.HK) 2025年度医疗健康大会简报披露,集团业务及财务状况依然强健,对2024年实现预期收入增长充满信心,并预期2025年收入将较2024年实现加速增长。
2024年,集团新增151个项目,项目总数达817个。此外,于2024年通过研究(R)平台赋能7个分子研究服务的全球项目,并有权于近期收取约1.4亿美元款项,潜在总收款金额约达23亿美元(假设该等全球项目的所有里程碑均达成)。基于现有合同预期,2025年将有24个PPQ(工艺性能确认)项目。同时,爱尔兰生产设施亦将按计划预期于2025年产生利润。
公司将于1月15日(美国太平洋时间)出席第43届年度摩根大通医疗健康大会,会上将进行包含公司业务营运若干资讯的简报。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.